Mr. Chair, I'm not in a position to address the legislation, but I am in a position to tell the committee that for the first time in Canada, we are now setting up databases on drugs and on other products that will have all people and all drugs. So even if you wanted to do true post-market surveillance prior, you didn't have the information to do that type of work. You had to rely on the pre-marketing through clinical trials.
We're now in a position to move in that direction, obviously depending upon privacy considerations, etc., which I know can in fact be incorporated, and these studies can in fact be done. I think, as we're moving into the system--and it's basically there in British Columbia and Alberta, and it's moving very quickly in Saskatchewan and in P.E.I--over the next 18 months to two years we will see these systems in place. It's going to take some will to increase our post-marketing surveillance, because the data will in fact be there.